List of Bepreve drug patents
Bepreve is owned by Bausch And Lomb Inc.
Bepreve contains Bepotastine Besilate.
Bepreve has a total of 2 drug patents out of which 0 drug patents have expired.
Bepreve was authorised for market use on 08 September, 2009.
Bepreve is available in solution/drops;ophthalmic dosage forms.
The generics of Bepreve are possible to be released after 13 January, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(5 months from now) | |
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(1 year, 11 months from now) | |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic